Trial Profile
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 06 May 2023 Primary endpoint (Disease control rate (DCR)) has not been met, as per results published in the Targeted Oncology.
- 06 May 2023 Results assessing the efficacy and safety of FTD/TPI plus cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer, published in the Targeted Oncology.
- 03 Jul 2021 Results presented at the 23rd World Congress on Gastrointestinal Cancer